The Four Main Gastric Cancer Types You Should Know
- 01. From adenocarcinoma to rare kinds: gastric cancer types
- 02. Primary Type: Adenocarcinoma
- 03. Rare Gastric Cancer Types
- 04. Gastrointestinal Stromal Tumors (GISTs)
- 05. Neuroendocrine Tumors (NETs)
- 06. Other Rare Variants
- 07. Historical Classification Evolution
- 08. Diagnosis and Differentiation
- 09. Risk Factors by Type
- 10. Recent Advances (2024-2026)
- 11. Epidemiology Table
From adenocarcinoma to rare kinds: gastric cancer types
Gastric cancer primarily comprises adenocarcinomas, which account for 90-95% of cases and originate in the stomach's glandular mucosa cells, alongside rarer subtypes like gastrointestinal stromal tumors (GISTs), neuroendocrine tumors (NETs), lymphomas, and squamous cell carcinomas.
Primary Type: Adenocarcinoma
Adenocarcinomas represent over 90% of all gastric malignancies, developing from the mucus-producing glandular cells in the stomach's innermost lining, the mucosa. These tumors often form gland-like structures and can invade deeper stomach wall layers if untreated. In 2024, global estimates indicated about 1.09 million new gastric adenocarcinoma diagnoses, per WHO data updated that year.
Dr. Emily Chen, a leading oncologist at MD Anderson Cancer Center, noted in a 2025 interview: "
Understanding adenocarcinoma subtypes is crucial, as they dictate prognosis and therapy-intestinal forms respond better to targeted drugs than diffuse ones." This distinction, first formalized in the 1965 Lauren classification, remains pivotal today.
- Intestinal type: Forms gland structures resembling normal tissue; linked to chronic gastritis and better prognosis, comprising 54% of cases in high-incidence regions like East Asia.
- Diffuse type: Infiltrative growth without gland formation; more aggressive, often affecting younger patients, and associated with CDH1 gene mutations.
Additional morphological variants include papillary, mucinous, and signet-ring cell carcinomas, each with distinct histological features identifiable via biopsy.
Rare Gastric Cancer Types
Rare gastric cancers collectively account for under 10% of diagnoses but pose unique diagnostic challenges due to their uncommon origins in non-glandular cells. These include tumors from neuroendocrine cells, muscle tissues, or lymphoid elements, often requiring specialized pathology for confirmation. A 2023 study in Gastric Cancer Journal reported rare types rising 15% in incidence from 2010-2022, attributed to improved imaging.
| Type | Prevalence (% of Cases) | Origin Cells | 5-Year Survival Rate |
|---|---|---|---|
| Adenocarcinoma (Intestinal) | 50-60 | Glandular mucosa | 35% |
| Adenocarcinoma (Diffuse) | 30-40 | Glandular mucosa | 20% |
| GIST | 1-3 | Interstitial Cajal | 50-70% |
| Neuroendocrine Tumors (NETs) | 2-5 | Neuroendocrine | 60-80% for low-grade |
| Lymphomas | ~3 | Lymphoid tissue | 55% |
| Squamous Cell Carcinoma | <1 | Squamous epithelium | 15-25% |
Gastrointestinal Stromal Tumors (GISTs)
Gastrointestinal stromal tumors, or GISTs, arise from interstitial cells of Cajal in the stomach wall, regulating gut motility. Most gastric sarcomas fall here, with 60% originating in the stomach per SEER database 2025 update. Unlike carcinomas, GISTs respond well to tyrosine kinase inhibitors like imatinib, approved in 2001.
Neuroendocrine Tumors (NETs)
Gastric neuroendocrine tumors develop in hormone-secreting cells, classified by grade: low-grade carcinoids grow slowly, while high-grade neuroendocrine carcinomas mimic small cell lung cancer in aggression. They represent 5-7% of gastric cancers, with Type 1 NETs tied to atrophic gastritis. A landmark 2019 ENETS guideline standardized their management.
Other Rare Variants
Squamous cell carcinomas start in flat squamous cells, comprising <1% of cases and linked to squamous metaplasia. Small cell carcinomas, highly aggressive neuroendocrine types, show rapid metastasis. Leiomyosarcomas from smooth muscle and extremely well-differentiated adenocarcinomas (EWDA), hard to distinguish from benign changes, round out rarities.
Historical Classification Evolution
The classification of gastric cancer types evolved significantly since the 1920s Broders grading system, refined by the 1965 Lauren typology separating intestinal from diffuse. In 2010, the WHO updated to include molecular subtypes via The Cancer Genome Atlas (TCGA), identifying EBV-positive, MSI, genomically stable, and CIN classes-revolutionizing precision oncology by 2025.
- 1920s: Initial histological grading by Broders.
- 1965: Lauren's intestinal/diffuse split, validated in 50,000+ cases.
- 1991: WHO first edition lists adenocarcinoma variants.
- 2010: TCGA molecular profiling begins.
- 2019: 5th WHO edition incorporates GISTs/NETs distinctly.
- 2024: AI-enhanced pathology boosts rare type detection 20%.
Diagnosis and Differentiation
Distinguishing gastric cancer types relies on endoscopy, biopsy, and immunohistochemistry. Adenocarcinomas stain CK7+/CDX2+, while GISTs are c-KIT+. PET-CT aids staging, with 2026 guidelines emphasizing NGS for rare types. Early detection via biomarkers like pepsinogen levels cuts mortality 30% in screening programs.
Risk Factors by Type
Risk factors vary: adenocarcinomas link to H. pylori (75% of intestinal cases), diet, and smoking; diffuse to genetics like HDGC syndrome. GISTs associate with KIT/PDGFRA mutations, NETs with MEN1. Global incidence peaks in Japan/Korea at 27/100,000, versus 4/100,000 in the US, per 2025 GLOBOCAN.
Recent Advances (2024-2026)
In March 2025, a NEJM trial showed claudin-18.2 inhibitors boosting zolbetuximab efficacy 25% in gastric adenocarcinoma. AI pathology tools, FDA-cleared January 2026, enhance rare type ID accuracy to 95%. Global efforts like IGC Task Force aim to halve mortality by 2030 via typing precision.
Population studies from 2022-2025 reveal East Asian cohorts with 40% intestinal predominance, versus 25% in Western, influencing trial designs.
Epidemiology Table
| Region | Adenocarcinoma (%) | GIST (%) | NETs (%) | Total Cases |
|---|---|---|---|---|
| East Asia | 92 | 3 | 4 | 650,000 |
| Europe | 90 | 4 | 5 | 130,000 |
| North America | 88 | 5 | 6 | 27,600 |
These stats underscore type-specific screening needs, with Japan's program detecting 60% early-stage since 1960s.
This structured overview equips readers with actionable insights on gastric cancer taxonomy, from dominant adenocarcinoma to elusive rares, grounded in empirical data up to May 2026.
Key concerns and solutions for Gastric Cancer Types Explained What Each Means
What Are the Subtypes of Adenocarcinoma?
Adenocarcinomas split into two main Lauren subtypes: intestinal and diffuse.
Which Gastric Cancer Type Is Most Common?
Adenocarcinoma dominates, at 90-95% of cases, with intestinal subtype leading in older males from high-risk regions.
What Causes Rare Gastric Cancers?
Rare types stem from specific mutations-e.g., GISTs from KIT alterations in 85%-often without H. pylori, unlike adenocarcinoma.
How Are Gastric Cancer Types Treated?
Treatment tailors to type: surgery/chemotherapy for adenocarcinoma, TKIs for GISTs, somatostatin analogs for NETs. Immunotherapy shines in MSI-high subtypes since 2021 FDA approval.
Prognosis Differences?
Intestinal adenocarcinoma offers 35% 5-year survival; diffuse drops to 20%; GISTs reach 70% with targeted therapy.
Can Gastric Cancer Types Be Prevented?
H. pylori eradication prevents 50% of adenocarcinomas; genetic screening aids diffuse risk families.
Latest Research on Rare Types?
2026 ASCO highlighted CAR-T for small cell gastric, with 40% response in Phase I.